214 related articles for article (PubMed ID: 32354736)
1. Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.
Lau TS; Chan LKY; Man GCW; Wong CH; Lee JHS; Yim SF; Cheung TH; McNeish IA; Kwong J
Cancer Immunol Res; 2020 Aug; 8(8):1099-1111. PubMed ID: 32354736
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.
Wanderley CW; Colón DF; Luiz JPM; Oliveira FF; Viacava PR; Leite CA; Pereira JA; Silva CM; Silva CR; Silva RL; Speck-Hernandez CA; Mota JM; Alves-Filho JC; Lima-Junior RC; Cunha TM; Cunha FQ
Cancer Res; 2018 Oct; 78(20):5891-5900. PubMed ID: 30104241
[TBL] [Abstract][Full Text] [Related]
3. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
4. The Ability of Clinically Relevant Chemotherapeutics to Induce Immunogenic Cell Death in Squamous Cell Carcinoma.
He Z; Jing X; Dai X; Bao L; Yang X; Xiong Y; Li M
Front Biosci (Landmark Ed); 2024 Apr; 29(4):158. PubMed ID: 38682206
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Peng J; Hamanishi J; Matsumura N; Abiko K; Murat K; Baba T; Yamaguchi K; Horikawa N; Hosoe Y; Murphy SK; Konishi I; Mandai M
Cancer Res; 2015 Dec; 75(23):5034-45. PubMed ID: 26573793
[TBL] [Abstract][Full Text] [Related]
7. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Mabuchi S; Ohmichi M; Nishio Y; Hayasaka T; Kimura A; Ohta T; Kawagoe J; Takahashi K; Yada-Hashimoto N; Seino-Noda H; Sakata M; Motoyama T; Kurachi H; Testa JR; Tasaka K; Murata Y
Clin Cancer Res; 2004 Nov; 10(22):7645-54. PubMed ID: 15569997
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
10. Chromomycin A
Florêncio KGD; Edson EA; Fernandes KSDS; Luiz JPM; Pinto FDCL; Pessoa ODL; Cunha FQ; Machado-Neto JA; Wilke DV
Front Immunol; 2022; 13():941757. PubMed ID: 36439184
[TBL] [Abstract][Full Text] [Related]
11. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Garg AD; Elsen S; Krysko DV; Vandenabeele P; de Witte P; Agostinis P
Oncotarget; 2015 Sep; 6(29):26841-60. PubMed ID: 26314964
[TBL] [Abstract][Full Text] [Related]
12. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
13. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
14. Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro.
Liu H; Zhang G; Huang J; Ma S; Mi K; Cheng J; Zhu Y; Zha X; Huang W
J Transl Med; 2016 Apr; 14(1):104. PubMed ID: 27118139
[TBL] [Abstract][Full Text] [Related]
15. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
16. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
[TBL] [Abstract][Full Text] [Related]
17. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
[TBL] [Abstract][Full Text] [Related]
18. An ER-Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small-Cell Lung Cancer.
Wang L; Guan R; Xie L; Liao X; Xiong K; Rees TW; Chen Y; Ji L; Chao H
Angew Chem Int Ed Engl; 2021 Feb; 60(9):4657-4665. PubMed ID: 33217194
[TBL] [Abstract][Full Text] [Related]
19. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
[TBL] [Abstract][Full Text] [Related]
20. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
